AzTrials
AzTrials

Esophageal CancerPhase 4NCT01962272

The Effect of Nutritional Counseling for Cancer Patients

A Phase 4 study testing Weekly nutritional counseling and Forticare®. in people with Esophageal Cancer and Gastric Cancer, run by University of Copenhagen at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background and aims: Cancer-related malnutrition is multifactorial and related to a bad prognosis. The aim of this study was to investigate the effect of intensive, individual dietary counseling of patients in radiotherapy and/or chemotherapy for gynecologic-, gastric-, or esophageal cancer. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Esophageal Cancer, Gastric Cancer, Uterine Cancer
What is being tested?
Weekly nutritional counseling and Forticare®.
Could I receive a placebo?
No, everyone receives an active treatment
How many people
61 participants
Where
1 siteDenmark
Study dates
Jan 2010to Sep 2010
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult, consecutive outpatients referred for either palliative or preoperative chemotherapy and/or radiation therapy of cancers in the stomach or the pelvic area.

Who cannot join

  • Lack of ability to understand danish language and the instructions given

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Departmen of Oncology, Rigshospital

    Copenhagen, 2100 OE

Other trials in Denmark

About this study

Official title: Randomised Trial of the Effects of Individual Nutritional Counseling in Cancer Patients

Background and aims: Cancer-related malnutrition is multifactorial and related to a bad prognosis. The aim of this study was to investigate the effect of intensive, individual dietary counseling of patients in radiotherapy and/or chemotherapy for gynecologic-, gastric-, or esophageal cancer.

Read the detailed description

The prospective, randomized controlled unblinded study with 61 consecutive outpatients. All patients were stratified according to primary disease (esophageal-, gastric- or gynecological cancer). Patients were randomised using tin foil-lined sealed envelopes by the authors. The sample size was calculated using 2α = 0.05, 1-β = 0.80, expected Standard Deviation (SD) (weight-loss-%) of 2.24 and the corresponding Minimal Relevant Difference of 1.75.

Due to different diagnoses and treatments, the duration of the participation in the study varied between 5 and 12 weeks (average 7.2 weeks). In all cases follow-up was performed three months after the end of treatment.

All patients randomized to receive nutritional intervention were counseled by the same dietitian at baseline, and once a week during treatment and at follow-up after three months. The goal of the nutritional counseling was an intake that met the protein and energy requirements according to Harris-Benedict equation multiplied with an individual activity factor (1,1-1,5) and a stress factor (1,0-1,1). Daily protein requirements were estimated to 1,5 g/kg per day. Dietary intake was evaluated by 24-hour-recall food questionnaires at baseline, every week, at the end of the study and at follow-up. On the basis of information from the 24-hour recall food questionnaires and supplementary comments patients were counseled on an individual basis with the purpose to minimize nutritional symptoms that may relate to cancer cachexia and the cancer treatment. The main elements of the counseling were to explain the importance of nutrition in relation to the patients present situation, to explain the targets and to agree on specific dietary goals to be fulfilled until the next session.

The control group was nutritionally instructed by the nurses with the possibility to call for a dietician if needed.

Apart from nutrition the patients had the same care and therapy, including treatment of pain and side-effects to the treatment.

The dietary data were coded and analysed for energy and protein content using a computerised version of Danish food composition tables.

In addition to the counseling, the patients in the intervention group were offered a high-protein nutrition supplement containing n-3 fatty acids (Forticare®, Nutricia). The recommended daily dose contained 2531 kiloJoule (kJ), 33.8 g protein and 2.2 g EPA. The use of dietary supplements and compliance with dietary recommendations were monitored weekly by questionnaire, interview and counting of residual containers with supplements. The data collection included recording of anthropometric data including body weight and body composition, biochemical nutritional status, nutritional status according to The Nutrition Risk Screening (NRS), and 24-hour dietary interview.

All participants were weighed at baseline, every week, at the end of the study and at follow-up. For a more detailed analysis of the weight development, Bioelectrical Impedance Analysis (BIA) was applied to assess the body composition of each patient. Measurements were performed by the investigators using an ElectroFluidGraph with a current (I) of 330 micro ampere (μA) and a frequency of 50 kilo herz (KHz) and according to Kyle and colleagues.

Quality of life (QoL) was measured at baseline, at the end of the study and at follow-up by using a self-administered questionnaire European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 version 3.0. This instrument is a 30- item cancer specific questionnaire designed to measure cancer patients' physical, psychological and social functions. This questionnaire was chosen because it has been shown to be reliable and valid in a number of studies. The questionnaire includes six function scales (physical, emotional, cognitive, social, role and global health), three symptom scales (fatigue, pain, nausea, or vomiting) and six single items assessing symptoms and the financial impact of the disease. A questionnaire developed in a previous study was used to assess treatment related side effects at the end of treatment by each patient. The questions covered the categories diarrhea, nausea, vomiting, loss of appetite, flatulence, abdominal pain and other kinds of pain.

The micronutrient status of the patients was assessed by blood analysis. The blood samples were obtained at baseline, at the end of treatment and at follow-up (p-Hemoglobin, p-Cobalamin, p-Ferritin, p-Transferrin, p-Iron, p-Magnesium, p-Phosphate, p-Albumin, p- Zinc).

Being tested
Weekly nutritional counseling, Forticare®.
Keywords
cancer, radiotherapy, chemotherapy, nutrition, dietary counseling, quality of life
Medical subject headings
Esophageal Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Weekly nutritional counselingBehavioural

    The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.

  • Forticare®.Dietary supplement

Study groups in NCT01962272
Study groupRoleWhat they receive
Nutritional counseling and Forticare®ExperimentalWeekly nutritional counseling and Forticare®. The goal being an intake that met the protein and energy requirements according to Harris-Benedict equation multiplied with an individual activity factor (1,1-1,5) and a stress factor (1,0-1,1). Daily protein requirements were estimated to 1,5 g/kg per day. In addition to the counseling, the patients in the intervention group were offered a high-protein nutrition supplement containing n-3 fatty acids (Forticare®, Nutricia). The recommended daily dose contained 2531 kJ, 33.8 g protein and 2.2 g EPA.
Receives: Behavioral: Weekly nutritional counseling; Dietary Supplement: Forticare®.
ControlActive comparatorThe control group was nutritionally instructed by the nurses with the possibility to call for a dietician not related to the study if needed. No fixed schemes. Apart from the nutritional element the patients had the same care and therapy, including treatment of pain and side-effects to the treatment.
Receives: Behavioral: Weekly nutritional counseling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Accumulated weight-change in per cent

    The primary end-points were accumulated weight-loss or -gain in per cent of the weight measured between inclusion and end of treatment and between end of treatment and follow-up, respectively.

    Measured: up to 7.5 weeks

Secondary outcomes (1)
  1. Treatment related side effects and Quality of Life

    Secondary endpoints were treatment related side effects and Quality of Life.

    Measured: up to 7.5 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Oct 2013 (estimated)
  2. Study startJan 2010
  3. Primary completionMay 2010
  4. Study completionSep 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
61 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01962272
Sponsor's protocol ID
H-4-2009-135
Other IDs
H-4-2009-135
Status last verified
Oct 2013
First submitted
8 Oct 2013
Last updated
14 Oct 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Weekly nutritional counseling and Forticare®. in people with Esophageal Cancer and Gastric Cancer, run by University of Copenhagen at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Oct 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Accumulated weight-change in per cent (time frame: up to 7.5 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in